(Q36845231)

16 August 2017

1 reference

title

Th2-mediated anti-tumour immunity: friend or foe? (English)

1 reference

16 August 2017

Ellyard JI

1

1 reference

PubMed ID

17559575

16 August 2017

Simson L

series ordinal

2

1 reference

PubMed ID

17559575

16 August 2017

Parish CR

series ordinal

3

1 reference

16 August 2017

1 July 2007

1 reference

16 August 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

Tissue Antigens

1 reference

16 August 2017

70

1 reference

16 August 2017

1-11

1 reference

16 August 2017

1

1 reference

The three Es of cancer immunoediting

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Adoptive T-cell transfer in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Antigen-processing machinery breakdown and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Primary antitumor immune response mediated by CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Inhibition of angiogenesis by interleukin 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Tumor Rejection by Modulation of Tumor Stromal Fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Role of IL-13 in regulation of anti-tumor immunity and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Granulocyte depletion and dexamethasone differentially modulate airways hyperreactivity, inflammation, mucus accumulation, and secretion induced by rmIL-13 or antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Interleukin-10 and the immune response against cancer: a counterpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Altered immune responses in interleukin 10 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Murine interleukin-4 displays potent anti-tumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Human peripheral blood eosinophils induce angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Alternative activation of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Memory T(H)2 cells induce alternatively activated macrophages to mediate protection against nematode parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Distinct role of macrophages in different tumor microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Microenvironmental arginine depletion by macrophages in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Cytokines, tumour-cell death and immunogenicity: a question of choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

Cancer despite immunosurveillance: immunoselection and immunosubversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2007.00869.X

10.1111/J.1399-0039.2007.00869.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17559575